MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from common
stock subscription...
$1,879,110
Proceeds from notes
payable - related party
$1,147,700
Net cash provided by
financing activities
$2,349,618
Canceled cashflow
$677,192
Net increase
(decrease) in cash
$51,327
Canceled cashflow
$2,298,291
Payment of notes payable
- related party
$525,700
Payment of notes payable
$150,000
Payment to economic
injury disaster loan
$1,492
Stock based
compensation
$592,604
Amortization of discount on
royalty obligation
$477,436
Accounts payable and
accrued expenses
$286,839
Change in fair value of
royalty liability
-$279,511
Loss on settlement of
debt
-$187,514
Amortization of debt discount
$55,738
Depreciation and
amortization
$44,003
Amortization of right-of-use
asset
$40,056
Imputed interest for
related party advances
$36,376
Change in fair value of
upfront purchase price...
$7,426
Warrants issued in
connection with the sales...
$4,430
Net cash used in
operating activities
-$2,298,291
Canceled cashflow
$2,011,933
Net loss
-$3,508,763
Upfront purchase price
liability
-$357,364
Accounts receivable
$253,459
Deferred revenue, grant
-$56,590
Grant receivable
$52,026
Lease liability
-$40,057
Prepaid expenses
$32,137
Inventory
$9,828
Back
Back
Cash Flow
source: myfinsight.com
BioCorRx Inc. (BICX)
BioCorRx Inc. (BICX)